Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
07:04am, Monday, 07'th Jun 2021
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today presented an analysis of its Phase 3 AURORA 1 study
Aurinia Pharmaceuticals: New Data Leads To Revamped Valuation Model
08:00am, Sunday, 30'th May 2021
AUPH recently released long-term data for its lupus nephritis drug LUPKYNIS. It also hosted an earnings call to go over the first two months of sales data.
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
06:05am, Thursday, 27'th May 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate i
Aurinia Pharmaceuticals: Currently Presents An Excellent Entry Opportunity
07:57pm, Friday, 21'st May 2021
The price of Aurnia's shares is currently at an inflection point. I expect to see LupKynis sales figures skyrocket in the coming quarters.
Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients
07:58am, Friday, 21'st May 2021
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced a supportive interim analysis of its AURORA 2 continuation study evaluating Lupkynis (voclosporin) in lupus nephritis. Data will be presente
2 Grossly Undervalued Biotech Stocks That Could Double Your Money
10:00am, Wednesday, 19'th May 2021
Aurinia Pharmaceuticals and Agenus might be poised for a healthy growth spurt.
Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences
06:05am, Friday, 14'th May 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the executive management team will participate i
Is the Options Market Predicting a Spike in Aurinia (AUPH) Stock?
09:55am, Thursday, 13'th May 2021
Investors need to pay close attention to Aurinia (AUPH) stock based on the movements in the options market lately.
AUPH Stock: Over 10% Increase Intraday Explanation
03:00pm, Tuesday, 11'th May 2021
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) increased by over 10% during intraday trading. This is why it happened.
Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet
06:53am, Monday, 10'th May 2021
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has announced that The Lancet published its Phase 3 AURORA 1 study evaluating Lupkynis (voclosporin) in adults with lupus nephritis (LN). The study resul
Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet
06:05am, Monday, 10'th May 2021
VICTORIA, British Columbia & ROCKVILLE, Md.--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that The Lancet, an internatio
AUPH Stock: Over 15% Decrease Pre-Market Explanation
06:54am, Friday, 07'th May 2021
The stock price of Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) decreased by over 15% pre-market. This is why it happened.
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call Transcript
12:35am, Friday, 07'th May 2021
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2021 Results - Earnings Call Transcript
Why Aurinia Pharmaceuticals Stock Is Crashing Today
05:33pm, Thursday, 06'th May 2021
Expectations for the biotech's first-quarter sales may have been too high.
Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021
06:30am, Wednesday, 28'th Apr 2021
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that it will release its first quarter 2021 financial results on
